STAB
Income statement / Annual
Last year (2021), Statera Biopharma, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2021, Statera Biopharma, Inc.'s net income was -$174.41 M.
See Statera Biopharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
| Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$488.31 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$488.31 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$11.83 M
|
$5.26 M
|
$587.00 K
|
$3.62 M
|
$5.05 M
|
$6.50 M
|
$7.14 M
|
$9.65 B
|
$19.53 B
|
$22.50 B
|
| General & Administrative Expenses |
$18.41 M
|
$5.24 M
|
$2.23 M
|
$2.32 M
|
$2.50 M
|
$3.38 M
|
$6.36 M
|
$8.47 B
|
$12.04 B
|
$11.12 B
|
| Selling & Marketing Expenses |
$79.44 K
|
$2.41 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$18.49 M
|
$5.24 M
|
$2.23 M
|
$2.32 M
|
$2.50 M
|
$3.38 M
|
$6.36 M
|
$8.47 B
|
$12.04 B
|
$11.12 B
|
| Other Expenses |
-$1.49 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$28.83 M
|
$10.50 M
|
$2.81 M
|
$5.94 M
|
$7.55 M
|
$9.87 M
|
$13.50 M
|
$18.12 B
|
$31.56 B
|
$33.62 B
|
| Cost And Expenses |
$29.32 M
|
$10.50 M
|
$2.81 M
|
$5.94 M
|
$7.55 M
|
$9.87 M
|
$13.50 M
|
$18.12 B
|
$31.56 B
|
$33.62 B
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$1.13 M
|
$124.23 K
|
$0.00
|
$0.00
|
$263.65 K
|
-$99.49 K
|
-$1.09 B
|
$83.13 M
|
-$70.02 M
|
| Depreciation & Amortization |
$255.57 K
|
$947.00
|
$13.78 K
|
$18.18 K
|
$21.08 K
|
$63.46 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| EBITDA |
-$170.65 M |
-$10.96 M |
-$3.09 M |
-$4.80 M |
-$5.60 M |
-$6.36 M |
-$10.79 M |
-$14.42 B |
-$23.08 B |
-$30.05 B |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$3.53 M
|
-$1.59 M
|
-$409.85 K
|
$1.19 M
|
-$4.11 M
|
$3.70 M
|
-$1.85 M
|
$16.05 B
|
$5.81 B
|
$11.81 B
|
| Income Before Tax |
-$101.88 M
|
-$12.09 M
|
-$3.22 M
|
-$3.61 M
|
-$9.71 M
|
-$2.66 M
|
-$12.64 M
|
$1.63 B
|
-$17.26 B
|
-$18.23 B
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$72.53 M
|
$1.13 M
|
$124.23 K
|
$0.00
|
-$52.52 K
|
-$22.82 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$174.41 M
|
-$13.22 M
|
-$3.35 M
|
-$3.61 M
|
-$9.71 M
|
-$2.66 M
|
-$12.64 M
|
$1.63 B
|
-$17.26 B
|
-$18.23 B
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-4.97 |
-0.52 |
-0.13 |
-0.32 |
-0.87 |
-0.24 |
-1.79 |
0.6 |
-363.32 |
-451.87 |
| EPS Diluted |
-4.97 |
-0.52 |
-0.13 |
-0.32 |
-0.87 |
-0.24 |
-1.79 |
0.6 |
-363.32 |
-451.87 |
| Weighted Average Shares Out |
$35.11 M
|
$25.65 M
|
$25.65 M
|
$11.29 M
|
$11.19 M
|
$10.99 M
|
$7.06 M
|
$2.70 B
|
$47.51 M
|
$40.35 M
|
| Weighted Average Shares Out Diluted |
$35.11 M
|
$25.65 M
|
$25.65 M
|
$11.29 M
|
$11.19 M
|
$10.99 M
|
$7.06 M
|
$2.70 B
|
$47.51 M
|
$40.35 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
